INTRODUCTION
============

The consequences of smoking are devastating, yet approximately 20% of the world's population above the age of 14 continues to smoke \[[@ref1]\]. Although smokers indicate that they want to quit, success rates are low \[[@ref2]\], and over half of those who have made a quit attempt will relapse within a year \[[@ref3]\]. Because of the myriad caveats associated with the study of real-world smoking, the role of smoking cue (SC) exposure in relapse remains equivocal \[[@ref4]\]. However, SC-elicited craving persists as a key metric by which to assess the severity of nicotine use disorder because cues elicit conditioned responses such as craving and approach behavior \[[@ref5]-[@ref7]\]. Further, former smokers continue to view SCs as salient long after cessation, and often cite SC exposure as their reason for relapse \[[@ref8]\].

SCs increase neural activity in reward-related brain regions, independent of pharmacological withdrawal \[[@ref9]\], SC-induced craving can predict increased smoking behavior \[[@ref10]\], and SC-elicited neural activation in reward regions can predict relapse \[[@ref11]\]. Furthermore, decreased functional connectivity between a salience region (anterior ventral insula; avInsula) and an executive control region (the dorsolateral prefrontal cortex; dlPFC) during SC exposure predicts relapse, indicating that decoupling of salience and executive control regions contribute to SC vulnerability \[[@ref12]\]. Similarly, smokers with greater response in reward regions during SC exposure have greater difficulty quitting smoking \[[@ref13]\]. Collectively, these studies elucidate a select role of SC vulnerability in relapse.

The primary smoking cessation medications are nicotine replacement therapy, bupropion, and varenicline, all three of which reduce withdrawal from nicotine \[[@ref14]\]. Varenicline, the most effective and most commonly prescribed, has a second mechanism: before cessation, it blocks nicotine's reinforcing effects \[[@ref15],[@ref16]\]. Nonetheless, varenicline does not help most individuals to whom it is prescribed, as relapse rates remain high \[[@ref17]\]. In line with varenicline's mechanism, varenicline-responders could represent a subgroup of smokers whose vulnerability to relapse is coupled with nicotine reinforcement, while those who do not respond to varenicline may have unmet vulnerabilities such as those associated with SC exposure. Currently, there are no medications directly targeting SC reactivity to aid SC-vulnerable individuals.

GABA-B agonists inhibit dopaminergic afferents in reward regions, including nicotine-induced reward signaling \[[@ref18]\]. There is substantial evidence that the GABA-B agonist baclofen blocks conditioned drug-related behaviors and may target drug cue vulnerabilities in humans \[[@ref19]-[@ref22]\]. One functional magnetic resonance imaging (fMRI) study showed that baclofen reduced reward-related neural responses to cocaine cues in abstinent, treatment-seeking cocaine participants, however baclofen-induced changes from baseline could not be determined from that study \[[@ref23]\]. Another recent neuropharmacological study examined baclofen's effects on alcohol cue reactivity in abstinent alcohol use disorder (AUD) treatment-seeking patients relapse \[[@ref24]\]. Authors examined cue reactivity prior to and after two weeks of medication. Baclofen increased activity of the anterior cingulate cortex (ACC) and bilateral dlPFC while decreasing responses in the ventral striatum (VS) and orbitofrontal and insular cortices. Responses in the ACC and insula predicted time to relapse \[[@ref24]\]. Collectively, these studies suggest a common mechanism whereby baclofen blunts the neural response to drug cues, which could be a useful/necessary mechanism of blunting cue-induced craving in cue-vulnerable substance use disorder patients.

Using the quantitative technique of perfusion fMRI, we have shown that baclofen increases cerebral blood flow (CBF) in executive control regions, including the dlPFC and ACC, in the resting brain and blunts CBF in reward regions, suggesting tonic modulation of the brain at rest \[[@ref25]\]. Greater tonic activation of executive control regions, as operationalized by resting state neuroimaging, could be an indicator of nicotine use disorder improvement: greater tonic executive control may be necessary to avoid a lapse when encountering SCs \[[@ref26]-[@ref28]\].

In the present study, we seek to extend the findings of ourselves and others by determining whether baclofen-related changes in the resting brain are associated with SC-reactivity within cigarette smokers. Based on our previous findings and those of Holla *et al*. \[[@ref24]\], 2018 and Janes *et al*. \[[@ref12]\], 2010, described above, we hypothesized (1) that baclofen would increase CBF in the bilateral dlPFC and the ACC in the resting brain, and (2) that the increases observed in resting CBF would be associated with decreases in CBF during SC exposure in our a priori reward regions (i.e., ventromedial prefrontal cortex/medial orbitofrontal cortex \[vmPFC/mOFC\], VS, and avInsula) \[[@ref9],[@ref11],[@ref12],[@ref24],[@ref29],[@ref30]\].

METHODS
=======

All procedures were conducted at the University of Pennsylvania Center for Studies of Addiction. All procedures were approved by the University of Pennsylvania's Institutional review board (IRB No. 817101) and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. This study was pre-registered at ClinicalTrials.gov, with Identifier: NCT01821560.

Participants
------------

Participants were treatment-seeking cigarette smokers, 18−60 years old, who smoked at least 10 cigarettes per day (CPD) for the past 6 months. Interested volunteers were recruited by flyers, listservs, and word of mouth and completed an initial phone screen and, if eligible, an in-person consent and screening visit. After providing informed consent, participants completed the Fagerström Test for Nicotine Dependence (FTND) \[[@ref31]\] and underwent physical and psychiatric screening. Physical screening included a blood test to ensure general physical health, an EKG, a urine toxicology test to rule out the presence of psychoactive drugs, and a pregnancy test in females. Psychological screening ascertained any current severe psychiatric symptoms, or diagnosis of any substance use disorders (SUDs) other than nicotine (MINI; \[[@ref32]\]). Participants were excluded for current other SUDs, current Axis 1 DSM-IV disorder, an intellectual ability estimate score below 80 \[[@ref33]\], use of any other smoking cessation strategies, and any MRI contraindications \[[@ref34]\]. Potential contraindications were reviewed by the study physician, and participants were financially compensated for participation. Participants were randomized to receive either baclofen or placebo after their first MRI scan. The study design is illustrated in Figure 1.

Twenty-three baclofen recipients (BAC) and 22 placebo recipients (PBO) completed study procedures. One participant was excluded for abnormally large ventricles and one participant was excluded for insufficient signal-to-noise ratio in their resting-state data.

Subjective craving scores were excluded for two baclofen participants based on an error in assessment administration. Analyses were completed on the remaining 21 BAC and 22 PBO, except the SC-elicited craving analyses which included 19 BAC and 22 PBO. Participant characteristics are listed in [Table 1](#T1){ref-type="table"}.

Medication
----------

Study medication was manufactured and provided by Murty Pharmaceuticals, Inc., Lexington, KY, USA. The Investigational Drug Service at the University of Pennsylvania maintained and distributed medication in blister packs (randomized by medication group and sex). All study staff and participants were blinded to the medication administered. A nurse practitioner met with participants weekly to collect used pill packs (compensation was provided to encourage adherence), distribute new packs, and monitor adverse events and medication adherence/issues. The most common adverse event reported for baclofen is drowsiness. Based on pilot data conducted in our lab, we were able to accelerate the titration schedule used in our previous study \[[@ref25]\] without affecting side effects, including drowsiness. Similarly to Logge *et al*. \[[@ref22]\], 2019, we used a titration schedule wherein participants reached the full dose of 80 mg (20 mg q.i.d.) by day 4 ([Table 2](#T2){ref-type="table"}).

Study Design
------------

To determine the effect of baclofen on neural function and SC-elicited craving, we used a double-blind, placebo-controlled paradigm. At baseline, participants and study staff agreed upon a "Quit Date" on which participants would attempt to quit smoking. Importantly, this occurred after the second scan (Time 2, T2) to mitigate any of quitting smoking on brain endpoints. Participants were instructed to continue smoking as usual until their Quit Date. Participants began the medication regimen after their first scan (Time 1, T1). After three weeks of treatment, participants underwent a second perfusion fMRI scan session following the same scan protocol (T2). CPD were recorded at both timepoints. Participants then returned for their "Quit Week" appointment, at which time they received smoking cessation counseling and continued treatment for four additional weeks ([Fig. 1](#F1){ref-type="fig"}).

All MRI sessions occurred in the early afternoon, to minimize any confounding effects of time of day, or effects of participants' daily routines on study results \[[@ref35]\]. fMRI sessions included a pseudo-continuous arterial-spin labeled (*p*CASL) perfusion fMRI scan at rest and during a SC reactivity task. *p*CASL is an MRI tool providing an objective measure of neural activity, using magnetically tagged blood as an inherent tracer \[[@ref36]\]. Unlike blood oxygen level-dependent fMRI, perfusion fMRI is quantitative, providing a measure of blood flow measured in milliliters of blood/100 g of tissue/minute. This gives perfusion fMRI the unique advantage of providing a baseline measurement, and as such, it is ideal for studying the effect of pharmacological agents on neural activity \[[@ref36]\]. Furthermore, perfusion fMRI is particularly suited for longitudinal studies, as it is reliable and replicable for up to seven weeks \[[@ref37]\]. Finally, the quantitative technique of perfusion fMRI is ideal for measuring states that accrue slowly over time, such as craving generated by drug cues. Additionally, craving may persist after stimulus exposure, often extinguished only by smoking, thus perfusion fMRI is well-suited to our model in which stimuli are presented over several minutes.

At both timepoints, participants were non-abstinent to minimize potential confounds introduced by withdrawal and to minimize differences between groups in smoking behavior, both of which might affect neural responses. Participants smoked ad libitum throughout the day of their scan, and smoked one of their own cigarettes to satiety (ad libitum) approximately 25 minutes before data acquisition to minimize the influence of smoking on vasculature \[[@ref38]\], which affects blood flow in the brain. Baclofen has a short half-life (approximately 4 hours), thus participants took their medication (20 mg baclofen or matching placebo) 1−1.5 hours prior to the T2 session in the presence of study staff to ensure medication compliance and standardize dose time. To minimize "carryover" effects in neural response to SCs, non-SCs were presented before SCs \[[@ref39]\]. While it is customary in some paradigms to counterbalance stimuli across scans and across participants to minimize a confounding effect of stimulus order in the results, we have previously established that (1) order effects are negligible \[[@ref9]\], and (2) such counterbalancing can introduce a "carryover" effect in responses, as craving elicited by SCs, when presented first, are not completely extinguished by the time non-SCs are subsequently presented \[[@ref39]\]. Participants completed the Craving and Withdrawal Questionnaire (CWQ) to assess SC-elicited changes in craving and withdrawal before and immediately after the SC task \[[@ref9],[@ref40]\].

fMRI Stimuli
------------

Stimuli presented during the non-SC and SC scans comprised audiovisual clips, each nine minutes long, featuring actors differing in race, age, and sex, and either smoking-related or nonsmoking-related cues. Unlike BOLD fMRI, perfusion MRI provides an objective measurement of blood flow, which precludes the need for counterbalancing. As such, the non-SC video was presented before the SC video, to prevent carryover effects. To prevent practice effects, participants saw one of two similarly valanced SC and non-SC videos at their first scan, and the second set of videos at their second scan. The order of presentation of videos was pseudorandomized across subjects. The SC videos featured actors smoking, while using language explicitly designed to induce desire for a cigarette (e.g., "The cigarette I enjoy most is the first cigarette of the day"). The non-SC videos featured actors, but they were not smoking, and instead, told short stories unrelated to smoking and without smoking reminders. During the SC videos, subjects held one of their own cigarettes in their preferred hand, and a match was lit and extinguished, providing visual and olfactory stimuli to enhance neurophysiological and subjective cue reactivity. During the non-SC video, subjects held a freshly sharpened pencil.

Scan Protocol and Parameters
----------------------------

MRI scanning occurred on a Siemens 3.0 Tesla Trio whole-body scanner (Siemens AG, Erlangen, Germany), using a standard Transmit/Receive head coil. High resolution MR images were acquired using T1-weighted 3D magnetization-prepared rapid gradient echo (MPRAGE) scan (TR/TE/TI = 1,620/3/950 ms, flip angle = 90°, bandwidth = 150, voxel size = 1 mm^3^, matrix = 192 × 256, slices = 160). Two-dimensional *p*CASL perfusion fMRI was used to acquire resting baseline, SC, and non-SC scans. The resting scan protocol included 45 resting label/control image pairs (labeling time, 1.5 seconds; post-labeling delay, 1,000 ms; matrix, 64 × 64 × 18; flip angle, 90°; TR, 3.5 seconds; TE, 17 ms; slice thickness, 7.2 mm; voxel size = 3.44 × 3.44 × 7.2 mm). The SC and non-SC scan protocols each included 68 cue label/control image pairs (labeling time, 1.5 seconds; post-labeling delay, 1,500 ms; matrix, 64 × 64 × 18; flip angle, 90°; TR, 4 s; TE, 17 ms; slice thickness, 7.2 mm; voxel size = 3.44 × 3.44 × 7.2 mm).

Imaging Data Preprocessing
--------------------------

We performed image processing using Statistical Parametric Mapping 12 (SPM12, the FIL Methods Group, 2016), ASL toolbox \[[@ref41]\], Functional MRI of the Brain Software Library \[[@ref42]\] and custom scripts in MATLAB 2016a \[[@ref43]\].

Prior to the analyses, brain images were visually inspected for gross movement, structural abnormalities and whole brain coverage. Each participant's anatomical and ASL images were manually reoriented to the anterior/posterior commissure line (AC-PC line), to improve segmentation and normalization accuracy. The raw echoplanar imaging images were then realigned to correct for head motion using the method proposed by Wang \[[@ref44]\]. The mean ASL image was aligned to the anatomical image of each subject using the FSL Boundary Based Registration (BBR) approach \[[@ref45]\]. Using SPM, the anatomical image of each subject was probabilistically segmented into grey matter, white matter and cerebrospinal fluid to construct a binary brain mask \[[@ref46]\]. The brain mask was down-sampled to the MNI space using the BBR co-registration parameters, and was used to restrict the CBF computation within the mask. Thereafter, a CBF time series was obtained by pairwise control-label subtraction, normalizing by corresponding control image, and using a single compartment model with recommended parameters \[[@ref47]\].

Image Quality Control Assessment
--------------------------------

A mean CBF map was obtained using a Structural Correlation with Robust Bayesian (SCRUB) estimation approach \[[@ref48],[@ref49]\] to remove artifacts from ASL-CBF images. The quality of mean CBF maps for each subject was evaluated using an automated quality evaluation index (QEI) \[[@ref50]\], with output values between 0 (no signal) and 1 (highest signal). A QEI of 0.7 or above demonstrates high sensitivity-specificity, and thus was our criterion for inclusion in analyses. The anatomical images were normalized to the MNI space using FSL non-linear registration and this, coupled with the BBR transformation, was used to normalize the CBF maps to the MNI space. The normalized CBF maps were thereafter smoothed with a 5mm full width at half maximum Gaussian kernel. For group level analyses, each model included a global calculation of the mean voxel value within the image as a regressor of no interest for data normalization.

Demographics and Behavior Analyses
----------------------------------

We conducted all demographics and behavior analyses in R version 3.4.2 (<https://www.r-project.org/>) \[[@ref51]\]. Before, and immediately after viewing SCs, participants were verbally administered the CWQ, which included a question to probe craving: "On a scale of 1−7, with 7 as the highest and 1 as the lowest rating, how much do you crave a cigarette right now?" We calculated a change score for subjective craving (post-SC−pre-SC) such that a positive score indicates an increase in craving. We analyzed participants' responses using linear mixed models, in which subjective craving rating was the dependent variable, and group (BAC or PBO), timepoint (T1 or T2), and rating time (pre- or post-SC exposure) were included as fixed independent variables \[[@ref52]\]. We included participant ID as a random variable to provide each individual's intercept. The primary result of interest was a group-by-week-by- pre-/post-cue exposure interaction. We also examined each group separately via *post-hoc*paired *t*tests to determine potential differences between T1 and T2 SC-elicited craving.

Imaging Analyses
----------------

As in our previous work, all analyses included participants' sex and age as nuisance covariates. No other demographic or smoking characteristics were included in the model as there were no differences between groups in any relevant variables ([Table 1](#T1){ref-type="table"}). All results reported in a priori regions of interest (ROIs) were small-volume corrected (SVC) with a 5 mm radius around the previously identified clusters \[[@ref9],[@ref25]\] and passed family-wise-error (FWE) correction, as well as a Šidák correction for multiple comparisons \[[@ref53],[@ref54]\] at a statistical threshold of *p* \< 0.01. We used R and MANGO (<http://ric.uthscsa.edu/mango/mango.html>) \[[@ref55]\] to generate figures.

For hypothesis 1, that baclofen would increase CBF in cognitive control regions at rest, all participant's mean resting images were included in a full factorial analysis, to determine a group-by-timepoint interaction. Based on the literature, ROIs for examining the effects of baclofen on the resting brain were the ACC (−8, −14, 40) and right and left dlPFC (±51, 24, 33) \[[@ref12],[@ref24],[@ref25]\].

For hypothesis 2, that the baclofen-induced increase in ROIs at rest would be associated with a decrease in the reward response during SC-exposure, we calculated a change value from the resting data (T2-T1) in the ROIs and entered them independently as covariates in the SC-model at T2, as previously described \[[@ref26]\]. Based on the literature and our significant experience examining the brain substrates of SC-induced brain activity, ROIs included the VS, vmPFC, and avInsula \[[@ref9],[@ref24],[@ref29],[@ref56],[@ref57]\].

RESULTS
=======

Participant Characteristics
---------------------------

There were no differences in age, sex, race, ethnicity, education, IQ, FTND scores, CPD, pack years, or cannabis and alcohol use between BAC and PBO recipients ([Table 1](#T1){ref-type="table"}). A linear mixed model revealed an overall effect of CPD between the groups and timepoints, F(3,81) = 3.05, *p* = 0.033. However, there were no effects of timepoint b = −1.57, standard error (SE) = 1.78, *p* = 0.38, group b = 2.20, SE = 3.95, *p* = 0.58, or the interaction between group and timepoint, b = −2.77, SE = 2.50, *p* = 0.27.

Adverse Events
--------------

There were no differences between BAC and PBO groups in total number of adverse events *t*(33) = 1.56, *p* = 0.13, *d*= 0.48. Because sedation, or "drowsiness," is the adverse effect most commonly associated with baclofen, we examined it separately. There was no difference between groups in sedation, *t*(36) = 1.32, *p* = 0.20, *d*= 0.42.

Smoking Cue-elicited Craving
----------------------------

Two participants' SC-elicited craving data were missing. Of the remaining participants, a linear mixed model revealed an overall effect, F(3,78) = 2.95, *p* = 0.038. There was an effect of timepoint, b = −1.32, SE = 0.49, *p* \< 0.01, no effect of group, b = −1.59, SE = 1.07, *p* = 0.14, and an interaction effect between timepoint and group b = 1.36, SE = 0.68, *p* = 0.047. *Post-hoct*tests revealed that this effect was driven by a reduction in SC-elicited craving in baclofen participants from T1 to T2, *t*= 2.90, *p* \< 0.01 ([Fig. 2](#F2){ref-type="fig"}), whereas there was no change in placebo participants between timepoints, *t*= −0.09, *p* = 0.93.

Imaging Results
---------------

All imaging results can be viewed in detail at ArielKetcherside.com. For our first hypothesis, that baclofen would increase resting brain activity in cognitive control regions, we performed a full factorial model in SPM12. This showed a timepoint-by-group interaction such that BAC participants had greater resting activation in the right dlPFC at T2 and compared to PBO (Z = 2.78, SVC *p* ~FWEcorr~ = 0.03, [Fig. 3A](#F3){ref-type="fig"}, see S1 for boxplot). There was no effect of timepoint on resting state CBF in our other ROIs, the ACC or the left dlPFC in BAC.

Given our second hypothesis, that baclofen-induced change in CBF within our ROIs at rest would associate with a decrease in the reward response during SC exposure, we extracted the values from the ROI wherein we saw an effect, the right dlPFC (calculated as T2-T1) and used them as covariates in the SC T2 model, as previously described \[[@ref26]\]. We found that the baclofen-induced increase in right dlPFC at rest was associated with a decrease in neural response in the vmPFC (Z = 4.33, *p* ~FWEcorr~ = 0.002) and left avInsula (Z = 3.85, SVC *p* ~FWEcorr~ = 0.002) during SC exposure ([Fig. 3B](#F3){ref-type="fig"}).

*Post-hoc* Brain-behavior Correlations
--------------------------------------

We performed a *post-hoc*analysis to determine if baclofen-induced changes in neural response to SCs correlated with subjective reports of SC-induced craving. First, we performed a full factorial analysis to identify a stimulus (SCs and non-SCs)-by-timepoint (T1 and T2) interaction effect on neural changes in SC response during treatment in both the baclofen and placebo groups. We then extracted the average value from a 5 mm sphere surrounding the peak voxel of the SC ROIs and examined whether these values correlated with the magnitude of change in SC-induced ratings for craving from T1 to T2. We observed a trend toward correlation between the magnitude of the decrease in SC-craving and the magnitude of the decrease in the left avInsula from T1 to T2 (−38, 14, −16), r = 0.36, *p* = 0.06 and in the vmPFC (4, 22, −14), r = 0.35, *p* = 0.07, the two regions previously identified in our testing of hypothesis 2. While these do not pass the "bright-line fallacy" threshold of significance \[[@ref58]\], or the Šidák correction for multiple comparisons that would be most prudent for interpretation as stand-alone results (*p*~adjusted~ \< 0.03) \[[@ref53],[@ref54],[@ref59]\], we present them here for interpretation in the context of our overall results. While further examination is necessary, these preliminary findings suggest that, the more BAC participants exhibited reduced activation in limbic regions, which have been shown throughout the literature to be associated with craving, the less SC-craving they reported ([Fig. 4](#F4){ref-type="fig"}). The same analysis in PBO participants showed no correlations.

Additional *post-hoc*analyses on this data set are provided at ArielKetcherside.com.

DISCUSSION
==========

We examined baclofen's effects on the resting brain in a priori cognitive control regions (ACC and dlPFC) and relationships between baclofen-induced resting changes and response to SCs in reward regions (vmPFC, VS, avInsula). Results indicate that baclofen increased resting right dlPFC activation, which was associated with a decrease in left avInsula and vmPFC SC-elicited activation. Further, while both groups reported SC-elicited craving prior to medication (T1), only baclofen-treated subjects showed reduced SC-elicited craving during treatment (T2). Our findings align well with those of Holla and colleagues \[[@ref24]\] who showed that baclofen increased activity in the dlPFC and decreased activity in the insula in AUD patients during alcohol cue exposure that subsequently predicted time to relapse, suggesting a common mechanism for mitigating craving across substances of abuse.

Our finding that baclofen increased dlPFC activation at rest replicates our previous findings \[[@ref25]\] and is consistent with literature implicating the dlPFC in recovery from substance use disorders \[[@ref24],[@ref60]-[@ref62]\]. The prevailing theory uniting these studies postulates that increased resting activity in the dlPFC can improve individuals' ability to mitigate conditioned responses that lead to relapse. The dlPFC is a hub of inhibitory control within the executive control network \[[@ref63]\], and during SC-reactivity, it integrates cue perception, craving, and behavior planning to seek or avoid SCs \[[@ref64]\]. Thus, the baclofen-induced increase in resting dlPFC observed here could indicate a similar increase in tonic executive control, enabling participants to self-regulate reactivity to SCs.

When included as a covariate in the model assessing SC-reactivity, the BAC-induced increase in resting dlPFC activation predicted a decrease in left avInsula activity in response to SCs, indicating that, the greater the tonic dlPFC activation, the less the avInsula responded to SCs. The insula integrates sensory, salience, and executive control networks, and the avInsula is associated with subjective "urge" for drugs in response to drug cues \[[@ref9],2[@ref9],[@ref64]-[@ref68]\]. Janes *et al*. have shown that avInsula activation in response to SCs predicted relapse during subsequent smoking cessation attempts \[[@ref11],[@ref12]\] and that decreased anterior insula-dlPFC functional connectivity during SC exposure predicts relapse \[[@ref12]\]. In line with this work, our findings suggest that the greater the tonic activation of the dlPFC, the less the avInsula responds to SCs, which could potentially prevent relapse. Associations between the left avInsula and craving have been observed repeatedly in the SC literature, however the right insula has also been implicated, and thus the laterality of our results should be addressed \[[@ref11],[@ref12]\]. One such explanation lies in previous work suggesting that the left avInsula responds more to positive stimuli than the right \[[@ref69]\]. As our SCs are highly appetitive, the left avInsula may have been more engaged during SC exposure prior to medication, such that baclofen's effects are observable to a greater extent on the left side. Baclofen's modulation of the dlPFC was also associated with a decrease in vmPFC response to SCs. This is congruent with literature showing that vmPFC activation during SC exposure is associated with craving, while its reduced activity is associated with smoking cessation interventions and reduced craving \[[@ref26],[@ref30],[@ref70]\]. Collectively, results suggest a mechanism by which baclofen may blunt SC-responsivity, and thereby prevent SC-induced relapse.

Additionally, *post-hoc*analyses in baclofen participants showed that the magnitude of baclofen-induced decreases in neural response to SCs in the avInsula and vmPFC (T1-T2) trended toward correlation with the magnitude of the decrease in subjective reports of SC-induced craving (T1-T2). In other words, the more BAC participants exhibited reduced activation in limbic regions, which have been established within the literature as mechanisms of craving, the less SC-craving they reported. While these correlations were small and only trended toward statistical significance, we note that patterns in the data are notable, given the small range of possible answers to the craving questionnaire (1−7) and the ensuing double subtraction of the scores. Given that these results link our imaging and behavioral findings, they further support our hypothesis for the proposed mechanism of baclofen in SC-craving reduction. Furthermore, they are similar to our previous results \[[@ref26]\]. As such, this relationship should be examined further in future work with a more sensitive measurement.

We did not observe baclofen-induced increases in the left dlPFC at rest. Evidence for functional heterogeneity between the right and left dlPFC indicates the right is involved in hierarchical evaluation, while the left is involved in the evaluation of possible outcomes \[[@ref71]\]. Thus, tonic orientation toward identifying potentially relevant stimuli at rest \[[@ref72]\], without the need to evaluate potential outcomes, may have engaged the right dlPFC in our study. Thus, lateralization should be examined in future work.

Baclofen's effects did not extend to the VS in the current study. This could be due to individual heterogeneity within our sample, including sex and/or genetic differences \[[@ref56],[@ref73]\], and the inclusion of non-SC vulnerable individuals, all of which we are underpowered to examine. These null findings underscore the heterogeneity in response to baclofen, and the importance of differentiating SC-vulnerable individuals from other treatment seekers.

To date, most studies of baclofen for SUDs are for AUD, with equivocal results \[[@ref74]-[@ref76]\], perhaps partially because potential heterogeneity in treatment response has not been examined. To date, three AUD studies have included neuroimaging during alcohol cue exposure \[[@ref21],[@ref22],[@ref24]\], with modest samples and mixed findings, however, they all emphasize (1) that baclofen's mechanism of action may be through blunting cue reactivity and that (2) more work is needed to understand this mechanism. Logge *et al*. particularly showed a dose-response effect such that a higher dose of baclofen (75 mg/day) reduced heavy drinking days compared to a lower dose (30 mg/day), which also warrants consideration in future studies.

Additional smoking-cessation and relapse-prevention medications are necessary for smokers trying to quit, as the most commonly-prescribed agent, varenicline, does not help the majority of patients to whom it is prescribed \[[@ref17],[@ref77]\]. Our group previously showed that the mechanism by which varenicline reduces SC-reactivity is through an increase in resting lateral OFC activation, which predicts a decrease in SC-response in the medial OFC and ventral striatum \[[@ref26]\]. Contrasted with the regions affected by baclofen in this study, this differential neural response to varenicline suggests that the medications have different mechanisms of action. Notably, baclofen, but not varenicline patients show a reduction in avInsula response to smoking cues, and the avInsula is well-established hub of interoception and craving \[[@ref11],[@ref66],[@ref68]\]. In this vein, one might speculate that varenicline's limited effectiveness may be because it does not directly block SC-reactivity: in all previous varenicline studies examining SC-reactivity, participants continued to smoke during treatment, before assessment \[[@ref26],[@ref78],[@ref79]\]. Perhaps the repeated blockade of nicotine reward while smoking extinguishes conditioned associations between the cues and cigarettes. Thus, as Brandon and colleagues explicitly suggest, the observed blockade of SC-induced craving could occur through temporary SC-reward extinction \[[@ref78]\]. Thus, varenicline's action to block reinforcement suggests it may be more helpful for abstinence initiation in those whose vulnerabilities include avoidance of withdrawal and reward reinforcement \[[@ref16]\], while baclofen may act as a relapse- prevention agent in a cue-vulnerable subgroup, abstinent at treatment initiation. This previously unaddressed emphasis on the potential use of baclofen for relapse-prevention rather than abstinence-initiation could partially explain the discordant literature. As such, future studies may find it useful to design studies that explicitly test the usefulness of medications in abstinence-initiation and/or relapse prevention to address individual vulnerabilities.

Baclofen has several inherent advantages for use as a medication for smoking cessation. It is currently approved for muscle spasticity by the United States Food and Drug Administration \[[@ref80]\], has a history of safety, is not abused, and its generally benign adverse effects, when present, are well-documented \[[@ref81]\]. It is available in generic form and is cost-effective. Its short half-life (4 hours) suits its use as a relapse prevention medication on an as-needed basis: as SCs are often context-dependent (e.g., being surrounded by smokers at an event), an individual could take baclofen prospectively, on an as-needed basis. Thus, baclofen is affordable and carries minimal risk, with an acute mechanism of action precluding the need for daily dosage. Although baclofen's effectiveness as a smoking cessation aid was not tested here, it has shown promise in the few placebo-controlled studies that have tested it. In a paradigm similar to the current study, using the same dose of baclofen and setting the Quit Date to occur after 3 weeks of study participation, baclofen reduced CPD \[[@ref82]\]. In another study conducted in alcohol dependent smokers seeking treatment for both, baclofen increased the number of days of abstinence of co-use \[[@ref83]\]. While both of these preliminary studies show proof of concept for further clinical examination in treatment-seeking cigarette smokers baclofen's efficacy has been challenged \[[@ref76]\]. An additional factor that may underlie the mixed therapeutic profile of baclofen is individual response to medication. While some studies show that low doses (\~30 mg per day) are effective other studies show a dose response effect with higher doses showing more effectiveness \[[@ref22]\]. Marsot *et al*. \[[@ref84]\] recently identified a potential mitigating factor that may provide some insight. In this pharmacokinetic study the plasma concentration of baclofen showed marked interpatient variability that remained unexplained by a multitude of potential confounding factors.

Limitations and Future Directions
---------------------------------

Although this study is strengthened by its within-subjects, placebo-controlled, longitudinal design, it has limitations. First, the modest sample size precludes our ability to examine heterogeneity in response to SCs or to baclofen that may be introduced by additional factors such as individual pharmacokinetics \[[@ref84]\] that might be affected by sex, genetics, and hormonal variability \[[@ref40],[@ref73]\]. Further, to heighten homogeneity in brain response, a particular design feature was to minimize changes in smoking behavior across participants; participants were asked to 'smoke as usual' until after the on-medication testing day and smoked to satiety immediately before both test days, which precluded the ability to study its potential effectiveness as a relapse prevention agent. Despite this, the literature to date indicates that baclofen does not block reinforcement while smoking, but rather influences reward circuitry \[[@ref20],[@ref85]\]. Nonetheless future studies should examine baclofen's ability to block SC-reactivity explicitly in abstinent smokers.

Conclusions
-----------

To date, the majority of smokers remain unaided by first line available smoking cessation medications that act to mitigate withdrawal and block reinforcement. As SC reactivity is a known relapse predictor, additional treatment strategies that specifically target SC reactivity are crucial. Our results suggest that the GABA-B agonist, baclofen, mitigates the enhanced reward response to SCs, and that this occurs through an increase in tonic activation of the dlPFC, an executive control region. This mechanism is congruent with the theory gaining recognition in the field, that strengthening tonic executive functioning facilitates recovery from SUDs. Finally, the variable effectiveness of baclofen for SUDs documented to date may actually indicate a difference in cue-vulnerability vs. reward-sensitivity in treatment-seeking individuals. Thus, baclofen may be most effective in facilitating relapse prevention in cue vulnerable smokers who have already quit.

The authors wish to thank Santos B. Murty and Murty Pharmaceuticals, Inc. for providing the medication; the Investigational Drug Service at the University of Pennsylvania for management of study medication; Melanie Maron, MS for coordinating the study; the clinical staff at the University of Pennsylvania Center for the Studies of Addiction, for conducting physical and psychiatric evaluations and medication monitoring; and the MRI technicians at the Hospital of the University of Pennsylvania for conducting the scanning sessions.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.

**Author Contributions**

Conceptualization: Teresa Franklin. Data acquisition: Nathan Hager, Chaela Nutor, Nathanial Spilka. Formal analysis: Ariel Ketcherside, Kanchana Jagannathan. Analysis support: Sudipto Dolui, Hengyi Rao. Funding: R01 DA0303994 (Teresa Franklin), R01 DA029845 (Teresa Franklin), K23AA023894 (Reagan Wetherill), R01DA040670 (Reagan Wetherill), R03 AG063213 (Sudipto Dolui). Writing-original draft: Ariel Ketcherside. Writing-review: All authors.

![Study design. Participants underwent a double-blind, placebo-controlled study in which they received 20 mg q.i.d. baclofen or placebo. They participated in a functional magnetic resonance imaging (fMRI) session before randomization (T1), and a second session after three weeks of treatment (T2). At each session, one of two similarly valanced smoking cue (SC) and non-SC sets was presented in a pseudorandomized fashion to control for habituation.*p*CASL, pseudo-continuous arterial-spin labeled; MPRAGE, magnetization-prepared rapid gradient echo.](CPN-18-289-f1){#F1}

![Smoking cue-elicited craving before and after 3-weeks of medication. Participants were asked how much they craved a cigarette before and after seeing smoking cues. Smoking cue-induced craving scores were calculated by subtracting pre-session ratings from post-smoking cue (SC) ratings at each timepoint. Baclofen, but not placebo participants reduce SC-elicited craving from pretreatment (T1) to during treatment (T2). Translucent bars indicate 95% confidence intervals.](CPN-18-289-f2){#F2}

![The effects of baclofen on dorsolateral prefrontal cortex (dlPFC) in the Brain at Rest Predict responses to smoking cues (SCs). (A) Coronal, axial, sagittal, and 3D images showing a baclofen-induced increase in right dlPFC cerebral blood flow (CBF) in the brain at rest, Z = 2.95, *p* = 0.021. (B) The dlPFC increase in the brain at rest predicted a decrease in the neural response to SCs in the ventral medial prefrontal cortex, Z = 4.33, *p* ~FWEcorr~ = 0.002 (top 3D image) and the left ventral anterior insula, Z = 3.85, *p* ~FWEcorr~ = 0.002 (bottom 3D image). Coordinates are in MNI space. Clusters are defined via whole-brain voxel-wise analysis. Values are family-wise error (FWE) corrected.](CPN-18-289-f3){#F3}

![Baclofen's effects on brain response to SCs trends toward correlation with SC-elicited craving. (A) The magnitude of decrease in SC-induced craving (T2-T1) trended toward correlation with the magnitude of decrease in left avInsula activation (T2-T1), MNI coordinates (−38, 14, −16), r = 0.36, *p* = 0.06, as well as (B) the magnitude of decrease in the vmPFC, MNI coordinates (4, 22, −14), r = 0.35, *p* = 0.07. SC, smoking cue; T1, before baclofen; T2, during treatment with baclofen; avInsula, anterior ventral insula; vmPFC, ventromedial prefrontal cortex.](CPN-18-289-f4){#F4}

###### 

Demographics and smoking characteristics

  Variable                         Baclofen (n = 21)   Placebo (n = 22)   Group comparisons   
  -------------------------------- ------------------- ------------------ ------------------- ------
  Sex, male                        13 (62)             14 (64)            0.01                0.91
  Age                              38.9 ± 12           40.2 ± 12          −0.47               0.64
  IQ                               97.4 ± 12.1         103.8 ± 12.4       −1.64               0.11
  Race                                                                                        
  African American                 12 (55)             14 (64)            0.19                0.66
  Caucasian                        7 (33)              6 (27)             0.19                0.67
  Asian                            2 (10)              2 (9)              \< 0.01             0.96
  Ethnicity                                                                                   
  Hispanic                         1 (0.1)             3 (0.1)            \< 0.01             1.0
  Education                        13.3 ± 1.8          14 ± 1.8           −1.06               0.29
  Alcohol use                                                                                 
  Endorsed use                     12 (50)             13 (59.1)          0.02                0.87
  Drinks per drinking day, T1^a^   2.7 ± 2.10          3.1 ± 2.4          0.46                0.65
  Cannabis use                                                                                
  Endorsed use                     7 (31.8)            8 (36.4)           \< 0.01             1.0
  Days of cannabis use, T1^a^      5 ± 2.6             4.5 ± 2.4          0.23                0.82
  Smoking characteristics                                                                     
  FTND                             4.9 ± 1.5           4.9 ± 1.5          0.19                0.85
  Pack years                       16.6 ± 13.8         15.6 ± 12.6        0.23                0.82
  CPD                                                                                         
  T1                               14.4 ± 5.7          13.9 ± 4.8         0.35                0.73
  T2                               12.9 ± 7.5          9.5 ± 4.7          1.72                0.09

Values are presented as number (%) or mean ± standard deviation.

T1, before treatment; T2, on medication and after 3 weeks of treatment; FTND, Fagerström Test for Nicotine Dependence; CPD, cigarettes per day.

In participants who used this substance in the last 30 days, measured by the Timeline Follow Back. There were no differences between groups in any demographics or smoking characteristics.

###### 

Baclofen titration schedule

  Study day        8:00 AM   12:00 PM   4:00 PM   8:00 PM
  ---------------- --------- ---------- --------- ---------
  Day 1            PBO       10 BAC     PBO       10 BAC
  Day 2            PBO       10 BAC     10 BAC    10 BAC
  Day 3            PBO       20 BAC     20 BAC    20 BAC
  Day 4−7          20 BAC    20 BAC     20 BAC    20 BAC
  Week 2−7         20 BAC    20 BAC     20 BAC    20 BAC
  Week 8 Day 1−2   PBO       20 BAC     20 BAC    20 BAC
  Week 8 Day 3−4   PBO       20 BAC     PBO       20 BAC
  Week 8 Day 5−6   PBO       10 BAC     PBO       10 BAC
  Week 8 Day 7     PBO       PBO        PBO       PBO

Baclofen (BAC) was titrated up to full dose (week 1) and tapered down (week 8) to mitigate adverse effects, including drowsiness. Placebo medication (PBO) was used to ensure blinding during the titration process.

[^1]: These authors contributed equally to this study as co-first authors.
